Lazard is celebrating the recapture of one of its most valuable UK clients.
The investment bank advised the drugs group SmithKline Beecham, which is merging with the former Lazard client Glaxo Wellcome, on the sale of several products worth $2.9bn (€3.2bn) to Novartis and Roche. The sales will remove regulatory barriers to the merger.